Ritu Baral

Stock Analyst at TD Cowen

(0.68)
# 3,727
Out of 4,825 analysts
36
Total ratings
30%
Success rate
-21.46%
Average return

Stocks Rated by Ritu Baral

Palvella Therapeutics
Feb 5, 2025
Initiates: Buy
Price Target: $44
Current: $24.03
Upside: +83.10%
Sage Therapeutics
Nov 21, 2024
Maintains: Hold
Price Target: $10$9
Current: $7.49
Upside: +20.16%
Spero Therapeutics
Nov 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $0.67
Upside: -
AN2 Therapeutics
Nov 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.24
Upside: -
Avidity Biosciences
Oct 21, 2024
Maintains: Buy
Price Target: $56$78
Current: $32.69
Upside: +138.61%
Alnylam Pharmaceuticals
Oct 21, 2024
Maintains: Buy
Price Target: $282$371
Current: $255.13
Upside: +45.42%
Insmed
Aug 9, 2024
Maintains: Buy
Price Target: $75$98
Current: $72.64
Upside: +34.91%
Madrigal Pharmaceuticals
Mar 15, 2024
Maintains: Outperform
Price Target: $349$390
Current: $327.70
Upside: +19.01%
Sagimet Biosciences
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $3.93
Upside: -
Sarepta Therapeutics
Mar 22, 2023
Maintains: Outperform
Price Target: $125$175
Current: $62.78
Upside: +178.75%
Maintains: Outperform
Price Target: $32$21
Current: $14.58
Upside: +44.03%
Initiates: Outperform
Price Target: n/a
Current: $0.30
Upside: -
Initiates: Outperform
Price Target: n/a
Current: $10.77
Upside: -
Initiates: Outperform
Price Target: n/a
Current: $1.47
Upside: -
Initiates: Outperform
Price Target: n/a
Current: $23.73
Upside: -
Initiates: Outperform
Price Target: n/a
Current: $3.57
Upside: -
Initiates: Outperform
Price Target: n/a
Current: $1.62
Upside: -
Downgrades: Market Perform
Price Target: n/a
Current: $0.76
Upside: -
Downgrades: Market Perform
Price Target: n/a
Current: $621.10
Upside: -